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Abstract
The role of cells of the hematopoietic lineage in fibrosis associated with
interstitial lung disease (ILD) is controversial; whether monocytes solely differentiate
into macrophages that activate resident fibroblasts, or if they can also differentiate into
fibrocytes (CD45+/Col I+ cells) that then differentiate into fibroblasts has been debated.
By using systemic bleomycin to induce fibrosis in a bone marrow transplant and
transgenic mouse models, as well as using human lung tissue from a patient with
scleroderma-associated ILD, we studied the contribution of the hematopoietic lineage to
the fibroblast population using flow cytometry and single cell RNA sequencing. Further,
our studies revealed reasons why fibrocytes are lost when fibroblast cultures are
passaged. Finally, we evaluated how treatment of mice with a novel, water-soluble
version of caveolin scaffolding domain (CSD) called WCSD affects fibrocyte
accumulation and fibrosis in our animal model. We found that during fibrosis, fibrocytes
increase in number and in their expression of Col I both in the lung tissue and in the
bronchiolar lavage fluid (BAL). The appearance of Col I in CD45+ precursors occurs
after their recruitment into the lung. Interestingly, fibrocytes express higher levels of
monocyte/macrophage markers (CD45, CD16, CD68, CD206) than do CD45+/Col Icells. In vitro experiments demonstrated that CD45+/Col I+ cells are at first predominant
in fibroblast cultures, but then are lost progressively during passage. Furthermore, these
fibrocytes do not appear to grow in vitro in the absence of CD45-/Col I+ fibroblasts.
ix

Treating mice with WCSD inhibited fibrocyte accumulation as well as overall collagen I,
Tenascin C, α-sma, and HSP47 levels and vascular leakage. The decreased fibrocyte
accumulation may result both from decreased precursor recruitment due at least in part to
decreased vascular permeability and from decreased differentiation of fibrocytes from
CD45+/Col I- precursor monocytes. In summary, CD45+ cells accumulate in lung tissue
during fibrosis and contribute to pathological remodeling by differentiating into
myofibroblasts that overexpress ECM proteins and myofibroblast markers. Their
contribution to fibrosis can be inhibited by WCSD which serves as a surrogate for
caveolin-1, a protein known to be reduced in expression in multiple cell types from
patients with fibrotic lung disease.

x

Introduction
Fibrosis is a common underlying factor in many different diseases. In the Western
world, diseases with a fibrotic component are responsible for nearly 45% of deaths
(Wynn 2004). Indeed, fibrosis occurs in all the main organ systems, including the heart,
kidney, lung, liver, and skin (Masuda, Fukumoto et al. 1994, Sunamoto, Kuze et al. 1998,
Fischer and Du Bois 2012). When an injury or disease occurs, a series of cellular and
molecular processes begins that ultimately may result in tissue fibrosis. This is an
adaptive response that helps to close and repair wounds (Xie, Wang et al. 2018), and is
initially a beneficial process. However, if the fibrotic response occurs for an extended
period of time, it can become pathogenic and lead to excessive deposition of extra
cellular matrix (ECM) proteins, scarring, and loss of organ function that can ultimately
result in organ failure and death.
The fibrotic response to injury occurs in several stages (Wynn 2004, Rockey, Bell
et al. 2015). The initiation of fibrosis begins when an injury occurs to the tissue. After
injury, resident effector cells become activated and drive a series of processes that result
in the recruitment of various cell types (i.e., monocytes, macrophages, neutrophils, T
lymphocytes, and B lymphocytes), as well as tissue repair and replacement of damaged
and injured cells. The recruitment of inflammatory cells into the site of injury activates
fibroblasts/myofibroblasts to inappropriately deposit high levels of ECM proteins into the
tissue, ultimately leading to loss of organ function and fibrosis.
Interstitial lung disease (ILD), also called interstitial lung pneumonias, is a term
used to represent a large group of fibrotic diseases that occur in the lung. There are a
1

variety of stimuli that can lead to ILD including toxins, radiation, infections, and
autoimmune disorders (such as in systemic sclerosis/scleroderma (SSc)). ILD can also
occur idiopathically (Borchers, Chang et al. 2011). These diseases are characterized by
injury to alveolar epithelial cells, excessive recruitment of inflammatory cells, activation
and proliferation of fibroblast/myofibroblasts, over production of ECM, and hyperplasia
of fibroblasts and type II pneumocytes (Selman and Pardo 2002, Wang 2009).
Two of the more devastating forms of ILD are idiopathic pulmonary fibrosis (IPF)
and SSc related ILD, both of which are often fatal and carry a worse prognosis than many
cancers. More specifically, SSc is a systemic autoimmune disease that can involve nearly
every organ system in the body, and is characterized by dysfunction of endothelial and
fibroblast cells, small vessel vasculopathy, and the excessive production and deposition
of ECM proteins. Despite the fact that the disease can involve most organ systems,
disease progression to the lung is the leading cause of death for patients with SSc
(Solomon, Olson et al. 2013). Lung involvement can result in both ILD and pulmonary
hypertension (PH). PH is characterized by high blood pressure in the lung and right side
of the heart resulting from injuries to the vascular endothelium, and an increased
inflammatory response leading to ablation and narrowing of pulmonary arteries
(Solomon, Olson et al. 2013, Vonk Noordegraaf, Groeneveldt et al. 2016). Until recently,
there were no FDA approved treatments for these diseases. Two drugs, pirfenidone and
nintedanib, have since gained FDA approval for patients with IPF, and nintedanib was
approved recently for patients with SSc. Both appear to be modestly effective in slowing
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disease progression (Daccord and Maher 2016). However, the prognosis for patients is
still poor.
To study ILD, a variety of different animal models have been used to try and best
recreate the features of the disease in humans. Some of these methods include exposure
to insults such as bleomycin, cigarette smoke, fluorescein isothiocyanate, and silica (Lee,
Reese et al. 2014). The most commonly used model for ILD is treatment with the
antitumor antibiotic, bleomycin (Moeller, Ask et al. 2008, Mouratis and Aidinis 2011).
Originally discovered in 1962, bleomycin received FDA approval in 1973 for the
treatment of various squamous cell carcinomas, but the drug has been limited in its
usefulness due to its potential to cause pulmonary fibrosis. Researchers have taken
advantage of this side effect and deliver bleomycin to rodents to induce pulmonary
fibrosis by a variety of methods. Administration of bleomycin is done either directly
(intratracheal or intraoral delivery), or systemically (intravenous, intraperitoneal,
subcutaneous, or through osmotic pump delivery) (Harrison Jr and Lazo 1987, Moore and
Hogaboam 2008, Aono, Ledford et al. 2012, Lee, Reese et al. 2014).
Historically, the cells that overexpress collagen in many fibrotic diseases, such as
ILD, were believed to be resident fibroblasts that have been activated through the release
of various cytokines. Once activated, the fibroblasts become myofibroblasts that
overexpress collagen and cause fibrosis. However, recent evidence suggests that some
fibroblast precursors are not resident fibroblasts. Rather, they may originate in the bone
marrow (BM) and are recruited into damaged tissue, or are derived from endothelial,
epithelial cells or pericytes present in the tissue that transdifferentiate into
3

myofibroblasts. Other potential sources of myofibroblasts have been reported including
mesenchymal stem cells (MSCs), perivascular adventitial cells, and smooth muscle cells
(Di Carlo and Peduto 2018).
In particular, BM derived monocytes differentiate into cells known as fibrocytes
that are defined by their expression both of the pan-leukocyte marker CD45 and the
fibroblast marker collagen I (Col I). Fibrocytes have been shown to be present in the
target tissues of several fibrotic diseases including the lung and skin in scleroderma (SSc)
and the heart of patients with cardiac disease (Quan, Cowper et al. 2004, Haudek, Xia et
al. 2006, Russell, Herzog et al. 2012). Since fibrocytes originate in the bone marrow,
fibrocytes or fibrocyte precursors must enter the circulation and be recruited to their
target sites. The recruitment of fibrocytes to their target tissues is presumably mediated
though the chemotactic action of chemokines via their interaction with cell surface
chemokine receptors on circulating cells. Previous research from our lab has suggested
that decreased levels of caveolin-1 in fibrocyte precursors promote the accumulation of
fibrocyte derived myofibroblasts in fibrotic tissues through: 1) the increased recruitment
of fibrocytes and/or their precursors (due to the upregulation of chemokine receptors) into
the tissue, 2) the increased differentiation of precursor monocytes into fibrocytes in the
tissue, and 3) the increased differentiation of fibrocytes into myofibroblasts that
overexpress ECM proteins thereby contributing to ECM remodeling (Lee, Perry et al.
2014, Reese, Perry et al. 2014, Lee, Reese et al. 2015). Besides differentiating into
myofibroblasts, fibrocytes promote fibrosis by secreting a variety of cytokines and
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chemokines that activate resident fibroblasts, promote inflammation and angiogenesis,
and recruit more fibrocytes and other cells to the target site.
The idea that fibrocytes serve as one of the major contributors to the population of
myofibroblasts that over overexpress collagen in fibrosis is somewhat controversial
(Moore-Morris, Guimarães-Camboa et al. 2014). This controversy arises from the use of
different methods by different investigators. Investigators who oppose the idea that BMderived cells contribute to fibroblast lineages may have over depended on Cre drivers for
lineage specificity and the failure to stain fibrotic tissues for CD45 (Moore-Morris,
Guimaraes-Camboa et al. 2014), a notoriously difficult protein to detect without proper
fixation. Previously reported CD45 staining in the lungs of bleomycin-treated mice has
been largely unconvincing (Inomata, Kamio et al. 2014).
Another recent study (Kleaveland, Velikoff et al. 2014) has be misinterpreted to
imply that fibrocytes are not important in lung fibrosis. In fact, this study only showed
that knocking out the collagen gene in BM-derived cells did not stop these cells from
becoming collagen+ in fibrotic tissue by IHC. Indeed, this study states that fibrocytes
normally express collagen mRNA. This study does not rule out the possibility that
fibrocytes normally serve as fibroblast progenitors or that fibrocytes normally contribute
to collagen expression during fibrosis. Moreover, in regard to their model, the authors
state that knocking out Col I in fibrocytes may have no effect on the severity of
bleomycin-induced disease because “other cell types might be compensating for loss of
functional fibrocytes”.
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Supporters of the importance of the monocye-fibrocyte-myofibroblast lineage
(Mollmann, Nef et al. 2006, Visconti and Markwald 2006, van Amerongen, Bou-Gharios
et al. 2008, Ruiz-Villalba, Simon et al. 2015) have observed a contribution of
hematopoietic cells to mesenchymal cell populations in fibrotic tissue using chimeric
mouse models wherein genetically-tagged (e.g. EGFP) BM cells are used to reconstitute
the BM of irradiated mice. The integrated, transgenic tag is then used to trace the fate of
marked cells. In summary, the EGFP genetic tag approach avoids possible problems with
Cre drivers and the retention of antigenicity during fixation.
Based on this background, our goal was to refine the methods to determine
whether fibrocytes (CD45+/Col I+ fibroblastic cells) truly exist, whether fibrocytes in the
fibrotic lung differ from fibrocytes in control lung tissue, and whether we could
determine why the fibroblasts that most people study appear to be CD45-. In addition, we
examined whether a therapeutic peptide, caveolin scaffolding domain (CSD), derived
from caveolin-1 affects fibrocytes. These studies have made extensive use of elegant
methods including transgenic mice designed for lineage tracing, flow cytometry, and
single cell sequencing.
Materials and Methods
Bleomycin Treatment of Mice and Harvesting of Tissue
The following procedures were approved by the MUSC Institutional Animal Care
& Use Committee. Ten-week old C57BL/6 mice (Charles River Laboratories, Boston,
MA) were maintained under specific pathogen-free conditions. Osmotic minipumps
6

(ALZET 1007D; DURECT Corporation, Cupertino, CA) containing either 100 μl saline
vehicle or bleomycin (100 U/kg) designed to deliver their contents at 0.5 μ l/h for 7 days
were implanted under isofluorane anesthesia under the loose skin on the back of the mice
slightly caudal to the scapulae. Pumps were removed on day 8-10.
Mice were sacrificed 21-28 days after the initiation of bleomycin administration.
Mice were sacrificed by isofluorane overdose, and the rib cage was opened to expose the
lungs. Mice were systemically perfused via the left ventricle with PBS. The left lobe was
then removed for flow cytometry, and the right lobes were collected for Western blots
and histology. Lung lobes that were used for Western blots were minced and
homogenized using a Tissue Tearor in 2 ml of 25 mM Tris (pH 8.0)-5 mM EDTA-5 mM
EGTA plus protease inhibitors [N-ethylmaleimide (10 mM), benzamidine (5 mM), and
phenylmethylsulfonyl fluoride (2 mM)] and phosphatase inhibitors [sodium fluoride (50
mM), sodium pyrophosphate (5 mM), and sodium orthovanadate (1 mM)]. The
homogenate was centrifuged for 3 min at 16,000 g. Finally, the supernatant was boiled
for 3 min in SDS-PAGE sample buffer for use in Western blotting experiments using the
indicated primary antibodies and appropriate secondary antibodies. If the right lobe was
used for histology, the left lobe was tied off and cut off. The remaining right lobes were
perfused with buffered zinc formalin fixative (Z-Fix; Anatech, Battle Creek, MI). Fixed
lung tissue was then removed and embedded in paraffin. Sections (4 μm) were stained
with hematoxylin and eosin (H&E) or Masson's trichrome or immunohistochemically.
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Cell Culture
All cell culture experiments were performed using DMEM with 4.5 g/L glucose,
L-glutamine, and sodium pyruvate containing 10% FBS with antibiotic/antimycotic
solutions. The cells were maintained at 37°C and 5% CO2.
Adhesion Assay
For the adhesion assay, cells were lifted using accutase for 10 minutes at 37°C.
The enzyme was inactivated with 10% DMEM/FBS, and the cells were spun for 5
seconds in the centrifuge to remove clumps. The supernatant was then transferred to a
new tube, and washed 2 times with DMEM/20 mM HEPES (pH 7.3), before being
resuspended to 300,000 cells/mL to be plated at 100 µl per well. Prior to plating the cells,
a non-tissue culture plastic 96-well plate was prepared by coating the wells with 100 µl of
0.1 M sodium bicarbonate in PBS containing either 0, 1, 3, 10, or 30 µg/mL of
fibronectin. The wells were then blocked for 1 hour with 200 µl of 10 mg/mL BSA in 0.1
M sodium bicarbonate. Cells were then added to the plate and incubated for 1 hour at
37°C and 5% CO2. After 1 hour, the plates were washed by submersion in warm PBS
two times with gentle shaking. The PBS was poured off and the cells were fixed for 5
minutes with 10% EtOH, and washed with PBS. The wells were then observed and
photographed on a fluorescent microscope, and images were quantified using Fiji –
ImageJ.
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Bronchoalveolar Lavage (BAL) Collection
Mice were sacrificed by isofluorane overdose, and the trachea was exposed. A
small incision was made in the top half of the trachea to allow the insertion of a blunted
20-gauge cannula. The cannula was then secured in place by tying a knot around the
inserted cannula in the trachea using suture thread. A 1 mL TB syringe containing
approximately 900ul of HBSS with 100 uM EDTA and antibiotic/antimycotic solution
was connected to the cannula, and used slowly to flush the lungs and recover the solution.
This process was repeated 4 times. After collection, cells were collected by centrifugation
(1200 rpm, 10 min, 4°C, Beckman GS-6R centrifuge) and the cell pellets resuspended in
1 ml ACK red blood cell lysing buffer (LONZA #10-548E) for 5 min to remove red
blood cells. The cells were then collected by centrifugation, washed, and resuspended in
the collection buffer.
EGFP Bone Marrow Transplantation
Ten to 14-week-old male C57BL6/Ly5.1 mice were prepared for bone marrow
transplantation using a single dose (9.0 Gy) of total body irradiation. Ten to 12-week-old
female EGFP/Ly5.2 mice were used as donors (Visconti et al., 2006). These mice express
EGFP under the control of a chicken beta-actin promoter and cytomegalovirus enhancer,
and have EGFP fluorescence in all cells, with the exception of erythrocytes and hair.
Briefly, donor mice were humanely sacrificed by CO2 inhalation. Bone marrow cells
were flushed from femurs and tibiae and washed in Ca++- and Mg++-free phosphatebuffered saline containing 0.1% BSA. A monodisperse suspension was prepared by
gentle trituration and filtering through a 40-μ m filter. Mononuclear cells were isolated by
9

density gradient centrifugation using Lympholyte-M (Cedarlane Labs, Burlingame, NC).
2.0×105 of these EGFP+ donor bone marrow cells were transplanted into the irradiated
recipients by tail vein injection. As previously described (Visconti et al., 2006),
peripheral blood chimerism was assayed at 30 days post-transplantation and multi-lineage
hematopoietic reconstitution was assayed at 60 days. Mice exhibiting high levels of
reconstitution were used in subsequent studies.
Collagen-EGFP Mice
These mice were generously donated by Drs. Carole Wilson and Lynn Schnapp
(while they were at the Medical University of South Carolina, now at University of
Wisconsin-Madison. Briefly, these transgenic C57BL/6 mice express EGFP under the
control of the Col1a1 promoter, allowing for the monitoring of type I collagen producing
cells based on EGFP fluorescence without requiring the use of antibodies (Yata, Scanga
et al. 2003).
Vav1-Cre;mTmG Mice
The Vav1-Cre;mTmG mice for this study were generated from two types of
commercially available mice from Jackson Labs, Vav1-Cre mice (B6.Cg-Tg(Vav1icre)A2Kio/J, stock #008610) and two-color fluorescent Cre reporter mice (B6.129(Cg)Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP/Luo/J, stock #007676), abbreviated ROSA-mTmG.
Vav1-Cre mice were obtained as hemizygotes (Vav1-Cre/+) whereas the ROSA-mTmG
mice were available as homozygotes (mTmG/mTmG). Both of these mice strains are
made on a C57BL/6 background. For use in the experiments, mice with the Vav110

Cre/+;mTmG/+ and Vav1-Cre/+;mTmG/mTmG were used. Under this genotype,
hematopoietic or BM derived cells (Vav1) will express the membrane targeted green
fluorescent protein (mG) via Cre mediated excision, while all other cells will express
membrane targeted tandem dimer Tomato (mT) (Figure 1) (Muzumdar, Tasic et al.
2007).

Figure 1. Vav1-Cre+/mTmG Diagram. Schematic representation showing Cre
mediated excision of the GFP protein in Vav1 expressing cells, while all other cells will
express the RFP, tdTomato.
CSD Treatment of Mice
Vav1-Cre+/mTmG mice were treated with either saline or bleomycin as described
above. Seven days after bleomycin administration, mice that received bleomycin began
receiving daily intraperitoneal (IP) injections of either vehicle or water soluble CSD
(WCSD) (concentration). Injection sites were alternated daily to minimize stress and
irritation to the abdomen of the mice. Mice were sacrificed 21 days after the
administration of bleomycin, and BAL, lung, and skin specimens were collected as
described above.
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Flow Cytometry
Lung tissue from mice was washed in cold DMEM and minced into small pieces
using fine surgical scissors. The tissue from each mouse was resuspended in 5 ml of
collagenase (1 mg/ml, Roche #10103578001) and shaken at low speed for 45 min at
37°C. Digestion was stopped by addition of 10 ml of DMEM/10% FBS. The sample was
passed through a 40 μm cell strainer to prepare a monodisperse cell suspension. Cells
were collected by centrifugation (1200 rpm, 10 min, 4°C, Beckman GS-6R centrifuge)
and the cell pellets resuspended in 1 ml ACK lysing buffer (LONZA #10-548E) for 5 min
to remove red blood cells. Lung cells were then collected by centrifugation, washed with
PBS, collected, and fixed and permeabilized for 20 min at 4°C in 1 ml Cytofix/Cytoperm
(BD #554722). Finally, cells were washed in FACS buffer containing Fetal Bovine
Serum (FBS) and saponin (BD Perm/Wash Buffer 554723) and resuspended in an
appropriate volume of FACS buffer prior to staining.
All incubations with antibody were done for 30 min at 4°C on a rocker at low
speed, all washes were done with FACS buffer, and all resuspensions were with FACS
buffer. Following washing, the immunolabeled cell suspension was analyzed by FACS
using a MoFlo Astrios (Beckman Coulter) or a Guava easyCyte 8HT (Millipore). At least
5,000 events were recorded per sample.
Single Cell RNA Sequencing
Experimental procedures followed established techniques using the Chromium
Single Cell 3’ Library v3 Kit (10x Genomics;
12

https://assets.ctfassets.net/an68im79xiti/40xc58fJNcCWipI1YIdXoS/a87092c1c1faa0f31
6c552a97229a268/CG000185_ChromiumSingleCell3_v3_FeatureBarcoding_CellSurface
Protein_UG_Rev_D.pdf). Briefly, cultured cells in single-cell suspension were labeled
with TotalSeq™-B anti-mouse Hashtag antibodies (Biolegend) and pooled in equal
proportions prior to loading onto a 10X Genomics Next GEM Chip B and emulsified
with Single Cell 3’ GEM beads using a Chromium™ Controller (10x Genomics). From
the barcoded cDNAs, gene expression (GEX) libraries were constructed using
Chromium™ Single Cell 3ʹ GEM Library Kit and hashtag oligo (HTO) libraries were
constructed using Chromium™ Single Cell 3ʹ Feature Barcode Library Kit (both from
10X Genomics) at the Translational Science Laboratory (Medical University of South
Carolina). RNA sequencing was performed on each sample (approximately 50,000
reads/cell for GEX libraries and 5000 reads/cell for HTO libraries) using a NovaSeq S4
flow cell (Illumina) at the VANTAGE facility (Vanderbilt University Medical Center).
For this study, lung cells were isolated from saline (n=3) and bleomycin (n=3)
treated Vav1-Cre+/mTmG mice and cultured in 10% DMEM and grown until near
confluence. Cells were lifted with accutase, washed, counted, and 50,000 cells from each
sample were incubated with mouse Tru-Stain FcX (Biolegend) for 10 minutes on ice (in
PBS + 1% BSA), then incubated with 1 ug anti-mouse Hashtag antibody for 30 minutes
on ice (in PBS +1% BSA) at a final concentration of 500 cells/µL. Labeled cells were
then washed three times with 1.5 mL of PBS + 1% BSA, resuspended in 50 µL of PBS +
0.04% BSA, and counted (Cellometer K2, Nexcelom Biosciences) before pooling. RNA

13

sequencing was the performed on each of the 2 pools (bleomycin and saline) containing
approximately 17,400 cells each.
Statistical Analyses
All numerical data are expressed as average ± standard deviation and were
analyzed using the Student’s t-test to evaluate statistical significance using GraphPad
Prism 7. In all figures, statistical significance is expressed as *p < 0.05, **p < 0.01, and
***p < 0.001.
Results
CD45+/Col I+ Cells are Increased in the Bleomycin Lung
To assess whether CD45+/Col I+ cells were elevated in fibrotic lungs, mice were
treated with either saline (n=11) or bleomycin (n=17) using the Pump Model (Lee, Reese
et al. 2014), and sacrificed at day 28. Total lung cells were isolated and double labeled
using antibodies for CD45 and an antibody against collagen Ia1 C-terminal propeptide
(Col I), and examined by flow cytometry. To establish the gating strategy for both CD45
and Col I, a fluorescence minus one (fmo) approach was used in which total lung cells
were incubated with CD45 only, or pro-collagen only antibodies (data not shown). For
this analysis using the MoFlo Astrios flow cytometer, the data from the 2D scatter plots
was split into four regions: Region I (CD45high/Col I+), Region II (CD45+/Col I+),
Region III (CD45+/Col I-), and Region IV (CD45-). Using this strategy, bleomycin
treated mice showed a significant increase in both Regions I (p < 0.001) and II (p < 0.01)
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(Figure 2). Interestingly. the saline treated mice contained almost no cells in Region I
(CD45high/Col I+).
To further examine the accumulation of CD45+/Col I+ cells in the lung, a time
course experiment was performed using the same parameters discussed above looking at
Days 3, 10, and 28 post-pump implantations (Figure 2). Saline treated mice (n=3) showed
low numbers of Region I (CD45high/Col I+) cells throughout the whole-time course
experiment, while bleomycin treated mice (n=3) showed a drastic increase in the number
of cells in Region I (CD45high/Col I+) that was significantly different than saline treated
mice at Day 28 (p < 0.001). In Region I (CD45+/Col I+), there was a significant increase
(p < 0.01) in the percentage of cells in both saline and bleomycin mice observed at Day 3
that was not seen at Days 10 and 28. Additionally, naïve mice were examined, and there
were no more than 4% of positive cells in Region I (CD45+/Col I+) (data not shown).
This increase in Region I (CD45+/Col I+) cells at Day 3, observed in both saline and
bleomycin, dropped after 10 days, and indicates the implantation of the pump as the
cause for this increase, rather than the contents of the pump. By Day 28, the percentage
of positive cells in the saline mice remained unchanged in Region I (CD45high/Col I+),
and stayed at the same percentage observed at Day 10 for Region I (CD45+/Col I+). For
the bleomycin treated mice there was a statistically significant (p < 0.05) increase in the
percentage of positive cells between the 10-day level and 28-day levels in Region I
(CD45high/Col I+) (not marked), that was also significantly different from the
percentages in saline mice. For Region I (CD45+/Col I+), the percentage of positive cells
followed the same pattern as the saline mice and stayed relatively unchanged from Day
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10 to 28. These experiments indicate that there is always a population of CD45+/Col I+
cells in the lungs, and there is a significant increase in both CD45high/Col I+ and
CD45+/Col I+ cells in the bleomycin treated mouse lung that accumulates over time.

Figure 2. Quantification of Fibrocytes in the Lung Over Time (A) Total lung cells
from both saline and bleomycin-treated mice were labeled with antibodies for CD45 and
Col I. Two-dimensional scatter plots are represented with CD45 on the y-axis and Col I
on the x-axis. The 2D plots were split into Regions I-IV and used throughout this
experiment. (B) The percent of total lung cells in Region I (CD45high/Col I+) and II
(CD45+/Col I+) are shown in terms of average ± SD of the 11 saline and 17 bleomycintreated mice sacrificed 28 days after the initiation of treatment. The percent of total lung
cells in Region I (CD45high/Col I+) (C) or II (D) 3, 10, or 28 days after saline or
bleomycin treatment is shown as the average ± SD for the following number of mice in
each category: 3-day saline, n=3; 3-day bleomycin, n=3; 10-day saline, n=3; 10-day
bleomycin, n=3; 28-day saline, n=11; 28-day bleomycin, n=17. Since there were no
differences observed in the percent of cells in Region I (CD45+/Col I+) between saline
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and bleomycin lung at day 3 and day 10, saline and bleomycin data were pooled before
determining the statistical significance in the decrease in percent of cells in Region I
(CD45+/Col I+) between day 3 and day 20. **p < 0.01, ***p <0.001.
HSP47 Levels are Increased in the Bleomycin Lung
The collagen chaperone, HSP47, has been found to be upregulated in the fibrotic
tissues of the heart, liver, and lung in humans as well as in experimental models of
fibrosis in mice. HSP47 plays an important role in the processing of procollagen, and can
serve as a surrogate marker for collagen expression (Lee, Reese et al. 2014, Otsuka,
Shiratori et al. 2017, Khalil, Kanisicak et al. 2019, Miyamura, Sakamoto et al. 2020). As
stated above, mice were sacrificed 28 days after the administration of either bleomycin or
saline, and total lung cells were isolated by collagenase digestion. The lung cells were
then stained with antibodies for CD45, Col I, and HSP47 (Figure 3). Regions I and II
examined using the gating strategy from (Figure 2) showed higher levels of staining for
HSP47 in the mice that had received bleomycin (Figure 3). There was a statistically
significant difference in HSP47 expression in both Regions I and II, where CD45+/Col I+
cells are located. Region I (CD45+/Col I-), containing CD45+/Col I- cells showed very
low expression of HSP47. Cells from both saline and bleomycin treated mice showed
expression of HSP47 in Region IV, where CD45- cells are located. Of note, in cells from
the bleomycin treated mice, there was a larger population of cells in Region 4 (CD45cells) with very high mean fluorescent intensity (MFI), than was present in the cells
isolated from the saline mice (Figure 3).
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Figure 3. Collagen Chaperone HSP47 in Regions I-IV. (A) Total lung cells were
labeled with antibodies for CD45, Col I, and HSP47 28 days after the treatment with
saline or bleomycin. Regions I-IV are shown in terms of average ± SD of the MFI of each
of 11 saline and 17 bleomycin treated mice. (B) Cells from Region I+II (CD45+/Col I+),
Region III (CD45+/Col I-), and Region IV (CD45-) were selected and the MFI of HSP47
in these cells was plotted. The bar at 1 x 102 represents that maximum MFI for unstained
cells. Note the increased MFI values observed in Regions I+II and Region I (CD45-) for
bleomycin treated mice. **p < 0.01
Circulating Fibrocytes
To determie if fibrocytes could be found in the blood, blood was collected at 3,
10, and 28 days after the administration of bleomycin or saline. Mice were sacrificed and
peripheral blood mononuclear cells (PBMCs) were isolated from blood collected by
cardiac puncture (Figure 4). Using the same gating strategy from above (Figure 3),
virtually no cells were detected in Region I (CD45high/Col I+) at any time point studied,
and very small numbers of cells were found in Region I (CD45+/Col I+). For both saline
and bleomycin-treated mice, there was a large difference in the number of cells found in
Region I (CD45+/Col I+) at day 3 versus the other two time points. However, there were
no real differences observed between saline and bleomycin at any of the individual time
points that were studied. This increase seen in the number of cells in Region I
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(CD45high/Col I+) and II at day 3 was also observed in the total lung cells (Figure 2).
These observations strongly suggest that after the implantation of the pump, cells from
the bone marrow are recruited into circulation in response to the inflammation caused by
the surgery. This is further reinforced by the observation that by day 10 and 28, it is very
difficult to detect cells in Regions I and II. These observations suggest that CD45+/Col I+
cells found in both Regions I and II are either recruited from the circulation at an early
time point, or that these cells do not fully differentiate into CD45+/Col I+ cells found in
Regions I and II until after they enter the lung.

Figure 4. Circulating Fibrocytes. (A) PBMCs were collected from both saline and
bleomycin-treated mice 28 days after pump implantation, and stained with antibodies for
CD45 and Col I. A 2D-plot from a bleomycin-treated mouse is shown with CD45 on the
y-axis and Col I on the x-axis (saline not shown). Note that there are almost no cells
present in Region I (CD45high/Col I+) and few cells in Region I (CD45+/Col I+), this
distribution of cells was observed in both saline and bleomycin-treated mice. (B) Percent
of PBMCs found in Region I+II expressed as the average ± SD for 3 saline and 3
bleomycin-treated mice at days 3, 10, and 28. Note the significant decrease in percent of
Region I+II from day 3 to 10 observed in both saline and bleomycin PBMCs. *p < 0.05
EGFP-BM Transplanted Mice Confirm that CD45+/Col I+ Cells are BM Derived
To confirm that the cells found in Regions I and II in the above experiments
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(Figure 2) were BM derived, a mouse model in which mice were first irradiated, and then
transplanted with the BM from an EGFP-mouse was used (Figure 5). Similar to the
experiments outlined above, saline (n=3) and bleomycin-treated (n=3) mice reconstituted
with BM from EGFP-mice were sacrificed after 28 days, and total lung cells were
isolated. The cells were then labeled with antibodies for CD45 and Col I and analyzed by
flow cytometry. A similar 2D profile was observed, and the cells were grouped into three
Regions: Region I containing all CD45+/Col I+ cells (Regions I+II from Figure), Region
II containing CD45+/Col I- cells, and Region 3 containing all CD45- cells (Figure 5).
Cells found both in Regions I and II (Regions I-III from below) were 100% EGFP+,
while cells found in Region III contained mostly EGFP- cells and only about 10%
EGFP+. These observations support the idea that BM derived cells can contain collagen,
and that this pattern of EGFP expression mirrors the expression of CD45, a hematopoietic
cell marker expressed on all BM derived cells.

Figure 5. CD45+/Col I+ Cells are BM derived. (A) To confirm that the cells in Regions
I and II (CD45+) where BM derived, total lung cells were isolated from saline (n=3) and
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bleomycin (n=3) mice reconstituted with bone marrow expressing EGFP, and stained
with CD45 and Col I. Bleoymcin-treated lung cells are shown. (B) Cells in the defined
regions 1-3 are shown in 1D plots of MFI for GFP. Nearly 100% of cells in Regions 1-2
were positive for GFP, while cells in Region 3 were only 10% positive for GFP.
Additionally, lung tissue was collected for IHC analysis from bleomycin and
saline-treated mice 28 days after pump implantation, and was stained with antibodies for
Col I and EGFP (Figure 6). Both saline and bleomycin treated mice had EGFP positive
cells in their lungs, but the bleomycin mouse lung had considerably more EGFP positive
cells and this staining overlapped with the increased collagen staining seen in the
bleomycin lung. This observation supports the idea that many EGFP-positive cells from
transplanted BM end up in the fibrotic lung as collagen positive cells.

Figure 6. BM-GFP+ Cells are Col I+ in the Lung Tissue. Lung tissue was stained with
antibodies for Col I (red) and GFP (green) for immunofluorescent analysis. Staining
revealed an increase in Col I expression in the bleomycin-treated mouse, and many of
these cells also expressed GFP indicating their hematopoietic origin.
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Collagen-EGFP Mice
To further characterize CD45+/Col I+ cells by flow cytometry, mice that express
EGFP under the collagen promoter were used to allow for further examination of cells
that were CD45+/Col_EGFP+ without relying on the use of an anti-collagen antibody.
Ten to 12-week old collagen-EGFP mice were treated with bleomycin (n=3) or saline
(n=3) using the pump model and sacrificed after 21 days. Total lung cells from these
mice were double labeled with antibodies for CD45, and various monocyte/macrophage
markers, and examined by flow cytometry (Figure 7). A significant increase in the
number of CD45+/Col_EGFP+ cells was observed in the bleomycin-treated mouse
compared to the saline mouse. This result was similar to the data we obtained using lung
cells from both C57BL/6 mice (Figure 2), and EGFP-BM transplanted mice (Figure 6).

Figure 7. CD45+ Cells from Bleomycin-Treated Mice Express Col I at Enhanced
Levels. (A) Total lung cells were isolated from Col_EGFP mice 28 days after bleomycin
or saline-treatment by osmotic mini pump, and labeled with CD45 antibody. Scatter plots
are presented with CD45 on the y-axis and Col_EGFP on the x-axis. (B) Fibrocytes
(CD45+/Col_EGFP+) are shown in terms percent positive ± SD showing a statistically
significant increase in the number of CD45+/Col_EGFP+ cells in the bleomycin lung.
***p < 0.001.
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Additionally, the cell populations that were CD45+/Col_EGFP- and
CD45+/Col_EGFP+ were examined for their expression of the monocyte/macrophage
markers CD16, CD68, and CD206. While similar low expression levels of CD16, CD68,
and CD206 was observed on CD45+/Col_EGFP- in cells from both saline and bleomycin
that were little more than unstained levels, they were present at much higher levels on
CD45+/Col_EGFP+ cells from the bleomycin-treated lung compared to the saline-treated
lung (Figure 8). These data further support the idea that CD45+/Col I+ cells increase in
the fibrotic lung and that they not only express the fibrosis markers Col I and HSP47,
they also express higher levels of monocyte/macrophage markers than CD45+/Col Icells. Moreover, the levels of these markers are higher in CD45+/Col I+ cells from bleo
than saline.

Figure 8. CD45+/Col_EGFP+ Cells Contain High Levels of Monocyte/Macrophage
Markers. To examine the expression level of monocyte/macrophage markers on
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CD45+/Col_EGFP+ cells, 1D plots were generated gated on CD45+/Col_EGFP- (blue)
and CD45+/Col_EGFP (red) based on the regions defined in Figure 7. Similar expression
levels of CD16, CD68, and CD206 were observed on CD45+/Col_EGFP- cells from both
saline and bleomycin-treated mice, while expression of these markers was much higher in
CD45+/Col_EGFP+ cells from bleomycin-treated mice than from saline. Interestingly,
expression levels for all markers examined was higher in CD45+/Col_EGP+ than
CD45+/Col_EGFP- cells.
Vav1-Cre;mTmG Mice Show the Hematopoietic Contribution to Myofibroblasts
To provide further evidence that hematopoietic cells can contribute to the
population of myofibroblasts found in the lung, transgenic mice containing hematopoietic
or BM derived cells (Vav1+) that express membrane targeted GFP via Cre mediated
excision were used. All other cells in this model will express membrane targeted
tdTomato. These mice were treated with either bleomycin (n=4) or saline (n=4) using the
pump model (Lee, Reese et al. 2014), and sacrificed at 21 days past pump implantation.
Both BAL and total lung cells were isolated from the mice, and double labeled with
antibodies for CD45 and Col I as well as various other monocyte/macrophage and
fibrosis related antibodies. The cells were then analyzed by flow cytometry (Figure 9 and
10). To establish a gating strategy for the analysis, both BAL and lung cells were run
through the flow cytometer without any primary antibody and are shown in Figures 9 and
10.
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Figure 9. Vav1-Cre+;EGFP+/Col I+ Cells are Increased in the Bleomycin Lung.
Total lung cells were isolated from saline (n=4) and bleomycin-treated (n=4) mice 21
days after pump implantation, and labeled with Col I antibody. The gating strategy was
established by using unstained cells for both saline and bleomycin mice seen in the top
two panels. A significant increase in the number of Vav1+/Col I+ cells was seen in the
bleomycin mouse lung, with no apparent change in Vav1-/Col I+ cells as seen in
previously reported experiments using other models. These experiments offer further
support that hematopoietic cells express collagen in increased numbers in fibrosis.

25

Figure 10. Vav1-Cre+;EGFP+/Col I+ Cells are Increased in the BAL from
Bleomycin-Treated Mice. Cells were isolated from the BAL of saline (n=4) and
bleomycin-treated (n=4) mice 21 days after pump implantation, and labeled with Col I
antibody. The gating strategy was established by using unstained cells for both saline and
bleomycin mice seen in the top two panels. A significant increase in the number of Vav1Cre+;EGFP++/Col I+ cells was seen in the BAL cells from the bleomycin mouse lung
compared to saline BAL. This observation was similar to the results obtained when
looking at total lung cells.
Examination of the data from the bleomycin and saline-treated mice showed a
significant increase in the number of Vav1-Cre+;EGFP++/Col I+ cells from both the
bleomycin BAL and lung as compared to the saline BAL and lung. This same
observation was observed when CD45 replaced Vav1-Cre+;EGFP+ on the Y-axis (Figure
11). These observations provide even further proof that hematopoietic cells can express
collagen and contribute to the myofibroblast population in fibrotic tissues. Additionally,
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the BAL and lung cells were further analyzed for their expression of
monocyte/macrophage markers, as well as selected fibrosis markers by gating on Vav1Cre+;EGFP++ (similar results were obtained by gating on CD45+ and are not shown).
Histograms showing representative MFI values for these cells are shown in Figure 12.
The analysis of Vav1-Cre+;EGFP+ cells from the total lung revealed a significant
increase in collagen. Additionally, there was a major increase in the number of cells
expressing the monocyte and macrophage markers CD11b, CD16, and CD68 in the
bleomycin-treated mice compared to the saline-treated mice (similar to the results in
Figures 7 and 8). Quantification of this analysis is shown in Figure 13.
In the analysis of the BAL cells, it was found that the number of cells expressing
the monocyte and macrophage markers, CD11b and CD16, was significantly increased in
bleomycin-treated mice compared to saline-treated mice. Similar to the Vav1Cre+;EGFP+ cells from the total lung, the number of cells expressing collagen was
significantly increased in the BAL of bleomycin-treated mouse.

Figure 11. CD45 and Vav1-Cre+;EGFP+ Show Similar Profiles When Labeled with
Col I. To examine if CD45 and Vav1-Cre+;EGFP+ are labeling the same cell
populations, total lung cells isolated from bleomycin-treated mice were labeled with
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CD45 and Col I antibodies, and 2D Scatter plots were made. (A) Scatter plot showing
CD45 on the y-axis and Col I on the x-axis. (B) Scatter plot showing Vav1-Cre+;EGFP+
on the y-axis and Col I on the x-axis. These scatter plots show that both CD45 and Vav1Cre+;EGFP+ give similar results when labeling fibrocytes. Similar results were also
obtained with saline-treated samples.

Figure 12. 1D Plots of Vav1+ Cells in Total Lung Cells. To visualize the differences in
monocyte/macrophage and fibrosis markers between saline (blue) and bleomycin-treated
(red) mice, 1D plots of Vav1+ cells are shown for (A) unstained, (B)
monocyte/macrophage markers, and (C) fibrosis related markers. Note the higher MFI
values in Vav1+ cells from bleomycin-treated (red) mice compared to saline (blue)
particularly for CD11b, CD16, CD68, CD206, and both collagens.
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Figure 13. Characterization of Vav1+ cells from BAL and Total Lung. (A) Cells
isolated from the lungs of saline (n=4) and bleomycin-treated (n=4) mice 21 days post
pump implantation were gated on Vav1-Cre+;EGFP+ expression and analyzed for
monocyte/macrophage markers and various fibrosis markers. CD11b and CD16 cells
were increased in the BAL of bleomycin-treated mice when compared to saline-treated
mice. Cells expressing both pro and telo-collagen were also significantly increased in the
bleomycin BAL. (B) Total lung cells from the same experiment were also analyzed for
the same markers 21 days post pump implantation, revealing significant increase in the
number of CD11b, CD16, and CD68 cells in the lung tissue. Both pro and telo-collagen
were also significantly increased in the total lung tissue of bleomycin-treated mice. *p <
0.05, **p < 0.01
Growth of Fibroblast from Vav1-Cre;mTmG Mice
As many researchers define fibroblasts as CD45- cells, it was important to
determine the fate of CD45+ (Vav1-Cre+;EGFP+) cells in standard fibroblast cultures.
Therefore, an experiment was performed where total lung cells were isolated from Vav1Cre;mTmG mice (n=3) and cultured under established fibroblast growth conditions.
Briefly, cells from total lung tissue were dissociated using collagenase, and were seeded
using DMEM+10% FBS in either T-25 flasks at a standard seeding density of 0.7 x 106 or
in 6 wells plates at a standard seeding density of 0.3 x 106, allowed to attach overnight,
and then non-adherent cells were washed off the next day. Cells were cultured and
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examined under a fluorescent microscope by assessing 3 randomly selected high-power
fields (HPF) from the plates at each time point. Passaging of cells was done with
Trypsin/EDTA. Cells that had not undergone any passages (P0), contained significantly
higher numbers of Vav1-Cre+;EGFP+ cells, than those that had been passaged once (P1)
(Figure 14). The number of Vav1-Cre+;EGFP+ cells at P0 remained constant throughout
the time points examined, and only appeared to decrease with passage. The same
statistically significant relationship was observed between cells that had been passaged
once versus cells that had been passaged twice (P2) showing that P1 cultures contained
higher numbers of Vav1-Cre+;EGFP+ per HPF than cells that had been passaged twice.
As was seen in P0, the number of Vav1-Cre+;EGFP+ cells remained fairly constant
within passage, and only decreased after passaging. Additionally, when viewed under the
fluorescent microscope, most of the Vav1-Cre+;EGFP+ cells have the spindle-like
appearance traditionally associated with fibroblasts. Of note, when observing the cultures
under fluorescent microscopy, Vav1-EGFP- cells (red) are difficult to count, and appear
very spread and nearly confluent, despite having a fairly standard shape under phase
microscopy.
To further examine the relationship between Vav1-Cre+;EGFP+ cells and
passaging in fibroblast growth conditions, a flow cytometric analysis of these cells was
performed at the indicated passages to examine if the same trend could be observed
(Figure 15). Indeed, at P0 high levels of Vav1-Cre+;EGFP+ cells were detected in
fibroblast cultures, while similar results were obtained using CD45 instead of Vav1EGFP. The percentage of Vav1-Cre+;EGFP+ cells or CD45+ cells significantly
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decreased from P0 to P1. This same trend in Vav1-Cre+;EGFP+ cells or CD45+ cells was
seen between P1 to P2, with almost no Vav1-Cre+;EGFP+/CD45+ cells observed by flow
cytometry. These observations suggest that Vav1-EGFP- “resident” fibroblast may be
more effective and efficient at establishing a presence on tissue culture plastic after
isolation from lung tissue potentially through an enhanced ability to spread on TC plastic
(see Figure 14, P1 and P2). The fibroblast cultures were additionally stained for Col I and
examined at P0, P1, and P2 to see if Col I levels were affected by the presence or absence
of Vav1-Cre+;EGFP+/CD45+ cells in cultures. No differences were observed between
any of the passages examined, indicating that Vav1-Cre+;EGFP+/CD45+ cells contribute
to the same level of collagen as do “resident” fibroblasts. These data demonstrate that
cells from the hematopoietic lineage can grow under typical fibroblast culture conditions,
but their numbers significantly decrease with passage. This observation may be one
explanation for why the contribution of hematopoietic cells to fibroblast populations
historically has been overlooked.
To evaluate the growth of Vav1+ cells in the absence of Vav1- cells, an additional
experiment was performed in which total lung cells isolated from bleomycin and salinetreated mice were incubated with anti- CD45 magnetic microbeads (MACS Miltenyi
Biotec), and positively selected using a magnet. The positively selected CD45+
populations were then plated under standard fibroblast conditions as described above.
Neither saline nor bleomycin cultures had any meaningful growth by 10 days, and the
experiment was stopped (data not shown). These experiments suggest that fibrocytes
(CD45+/Col I+) need some type of stimulation from resident cells.
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Low Seeding Densities Yield Fibroblast Cultures of Primarily Vav1-Cre+;EGFP+
Cells
To assess whether reducing the competition for space between Vav1Cre+;EGFP+ cells and resident fibroblasts allowed for improved growth of Vav1Cre+;EGFP+ fibroblasts, experiments were performed using low seeding densities. Total
lung cells isolated from saline and bleomycin-treated mice were seeded in either T-25
flasks at 0.35 x 106 or in 6 well plates at a concentration of 0.15 x 106, and allowed to
attach overnight, while non-adherent cells were washed off the following day. The cell
cultures were examined and photographed daily for growth under the fluorescent
microscope, and selected time points are shown in Figure 16. Both saline and bleomycintreated cells exhibited a similar pattern of growth. By seeding the cells at lower densities,
fibroblast cultures that were primarily EGFP+ were observed, and this phenotype was
maintained until confluency. A phase contrast photo of the cultures at day 14 was
included to show that the EGFP+ cells exhibited a typical spindle-like fibroblast shape.
These data further suggest that cells from the hematopoietic lineage can differentiate into
fibroblasts, and that previous studies may have overlooked their contributions to the
fibroblast/myofibroblast populations due to the use of traditional fibroblast culture
protocols.
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Figure 14. Vav1-EGFP Fibroblasts decrease with passage. To assess if cells with a
hematopoietic lineage can be grown and contribute to the fibroblast population, total lung
cells were isolated from Vav1-Cre;mTmG mice and grown under typical fibroblast
conditions. (10% FBS+DMEM, 37°C, and 5% CO2) (A) Using a fluorescent microscope,
photographs of the fibroblasts were taken at various time points, and a representative
HPF was chosen showing a decrease in the number of Vav1-Cre+;EGFP+ cells with
passage. (B) A quantification of the 3 randomly selected HPFs at the indicated time
points, revealing a significant decrease in the number of Vav1-Cre+;EGFP+ between P0
to P1 (p < 0.01), and between P1 to P2 (p < 0.01).
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Figure 15. Vav1-EGFP and CD45 Levels Decrease at the Same Rate With Passage.
To further validate the observation seen in Figure 14, fibroblast cultures isolated from
Vav1-Cre;mTmG mice as described above, were collected by accutase, washed, and then
labeled with an antibody for CD45 and Col I. This was done during P0, P1, and P2. At
P0, high levels of Vav1-Cre+;EGFP+ and CD45+ cells were observed in similar
numbers. After one passage, there was a significant decrease in both the levels of Vav1Cre+;EGFP+ and CD45+ cells as seen by the shift in the peak from the right to the left.
By the second passage, almost no EGFP+ and CD45+ cells were found in the fibroblast
cultures. Col I staining at all three passages shows that Col I levels were similarly high at
P0 when the cultures were heavily Vav1-Cre+;EGFP+/CD45+, and at later passages
when Vav-EGFP+/CD45+ levels had fallen. This experiment further validates the
observations that Vav1 and CD45 label the same cell populations, that these Vav1Cre+;EGFP+/CD45+ fibrocytes express Col I at levels similar to Vav1-EGFP-/CD45resident fibroblasts, and that these cells while initially dominant in fibroblast cultures,
decrease over time.
Growth of Vav1-Cre+;EGFP+ Fibroblasts from BAL
Because CD45+/Col I+ cells were also observed in the BAL collected from
bleomycin and saline-treated mice (Figure 10), experiments was performed to see if cells
from the BAL could be grown into typical fibroblast cultures. BAL fluid was collected
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from both bleomycin and saline-treated mice and plated at 0.2 x 106 cells per well in a 6
well plate, after overnight culture, unbound cells were removed by washing. The BAL
cells were cultured in three different growth conditions: 1. standard fibroblast growth
conditions (DMEM+10% FBS) 2. fibroblast conditioned medium (DMEM+10% FBS
from overnight fibroblast cultures) 3. co-cultured on pre-existing attached Vav1-EGFP(red) fibroblasts at about 60-70% confluency. The BAL cultures were observed and
photographed daily using a fluorescent microscope to monitor for growth. In the control
or standard growth conditions, there was little to no growth throughout all the time points
analyzed (Figure 17). The BAL cells grown in conditioned medium,

Figure 16. Low Seeding Density Yields Primarily Vav1-EGP+ Fibroblast Cultures.
Total lung cells from both saline and bleomycin-treated mice were isolated 21 days post
pump implantation, and plated at low seeding densities to reduce competition for space
and allowed to grow. For 6-well plates, a seeding density of 0.15 x 106 was used, and for
T-25 flasks, a seeding density of 0.35 x 106 was used. The fibroblast cultures were
photographed daily using a fluorescent microscope and the growth of Vav1-EGP+ cells
was monitored, similar results were obtained for cultures from both saline and
bleomycin-treated populations. By Day 14, both the plates and flasks had reached near
confluency and were composed of mostly Vav1-EGP+ cells. These cells also exhibited
long spindle like shapes typical of fibroblast cultures, and is shown in the Day 14/Phase
photo.
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Figure 17. Growth of Vav1-Cre+;EGFP+ Cells from BAL in Control Conditions.
BAL was isolated from saline and bleomycin-treated mice 21 days post pump
implantation, and were plated at 0.2 x 106 cells per well in a 6 well plate using standard
fibroblast growth conditions (10% FBS+DMEM, 37°C, and 5% CO2). Cells were
observed and photographed daily using a fluorescent microscope, and no growth of cells
was observed through all the time points checked.
showed some growth throughout the course of the experiment, but they ultimately failed
to fully expand and differentiate into fibroblast-like cells (Figure 18). The BAL cells that
were co-cultured on Vav1-EGFP- fibroblasts were able to expand and differentiate into
spindle-shaped fibroblast like cells (Figure 19). Both saline and bleomycin-treated BAL
cells gave the same results in culture, the only difference observed was in the total
number of cells harvested from BAL, with bleomycin-treated BAL containing 3x as
many cells as BAL from saline-treated mice. These experiments highlight the idea that
while cells from the hematopoietic lineage can differentiate into fibroblasts, they need
additional stimulation from resident cells to grow and differentiate. While secreted
growth factors may aid in the CD45+ fibroblasts ability to grow, it appears that secreted
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factors may be insufficient on their own, and that CD45+ fibroblasts require some type of
cell to cell contact for enhanced growth and differentiation.

Figure 18. Growth of Vav1-Cre+;EGFP+ Cells from BAL in Conditioned Medium.
BAL was isolated from saline and bleomycin-treated mice 21 days post pump
implantation, and were plated at 0.2 x 106 cells per well in a 6 well plate using
conditioned fibroblast growth media (10% FBS+DMEM, 37°C, and 5% CO2 collected
from fibroblast cultures after overnight culture). Cells were observed and photographed
daily using a fluorescent microscope, cells from both saline and bleomycin-treated mice
exhibited some growth and expansion by day 7, but ultimately failed to expand and were
dying out by day 10.

Figure 19. Growth of Vav1-Cre+;EGFP+ Cells from BAL in Co-Culture Growth
Conditions. BAL was isolated from saline and bleomycin-treated mice 21 days post
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pump implantation, and were plated at 0.2 x 106 cells per well in a 6 well plate containing
Vav1-EGFP- fibroblasts (red only) at 60-70% confluency, using standard fibroblast
growth media (10% FBS+DMEM, 37°C, and 5% CO2). Cells were observed and
photographed daily using a fluorescent microscope, cells from both saline and
bleomycin-treated mice had higher rates of attachment seen on day 1 than in either
control or conditioned medium. Furthermore, Vav1-Cre+;EGFP+ cells from both saline
and bleomycin-treated were able to expand and differentiate into spindle-shaped
fibroblast like cells.
Comparing the Adhesion Ability of Vav1-EGP+ Cells with Vav1-EGP- Cells
To compare the adhesion ability of Vav1-Cre+;EGFP+ cells to Vav1-EGFP- cells,
a series of experiments was performed using P0 fibroblasts isolated from Vav1Cre;mTmG mice (n=3). To perform these experiments, cells were first lifted using
accutase, washed, resuspended in DMEM/HEPES, and plated into 96-well plates that
were pre-coated with fibronectin at either 0, 1, 3, 10, and 30 µg/ml (Figure 20A). The
cells were then incubated for 1 hour at 37°C, before being fixed and washed for
observation on a fluorescent microscope. The images were quantified using ImageJ and
results are reported as Percent Area (Figure 20C). At 0 µg/ml, non-specific attachment in
the absence of fibronectin for both populations was low. Adhesion of the Vav1Cre+;EGFP+ (green) cells to fibronectin coated wells was nearly maximal at 1 µg/ml. In
contrast, Vav1-EGPF- (red) cell adhesion continued to increase up to the highest
fibronectin concentration of 30 µg/ml. Put another way, the Vav1-Cre+;EGFP+ (green)
cell adhesion was 90% as much at 1 µg/ml fibronectin compared to 30 µg/ml, while
Vav1-EGFP- (red) was only 20% as much. These data support the idea that
hematopoietic lineage derived fibroblasts are highly responsive to ECM proteins like
fibronectin that promote cell adhesion, growth, and differentiation (Klecker and Nair
2017).
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Suppression of Fibrosis in vivo by a Novel Version of CSD
The caveolin-1 derived peptide, CSD, has been shown to be effective at inhibiting
fibrosis in several studies (Tourkina, Richard et al. 2008, Lee, Perry et al. 2014, Reese,
Perry et al. 2014). Recently, we have developed a version of CSD better suited for drug
development because it is water-soluble. Here we studied how water-soluble CSD
(WCSD) would affect hematopoietic lineage derived fibroblast accumulation and fibrosis
progression in bleomycin treated mice. As described in the methods, mice were treated
with vehicle or bleomycin delivered over seven days by subcutaneously implanted
osmotic minipumps. There were three groups of mice: saline treated mice (n=4),
bleomycin-treated mice that received vehicle for two weeks starting on day 8 (n=4), and
bleomycin-treated mice that received WCSD for two weeks starting on day 8 (n=4). Mice
were sacrificed after 21 days, and BAL, lung, and skin tissues were collected. To assess
whether WCSD had an effect on fibrocyte accumulation in the lung, total lung cells were
isolated and stained with antibodies for CD45 and Col I, and flow cytometry was
performed using the Guava easyCyte 8HT. The saline treated mice showed a low amount
of fibrocyte accumulation in their lung as expected. Bleomycin-treated mice that received
WCSD showed >80% reduction of fibrocyte accumulation compared to mice that
received vehicle injections (Figure 21AB). Nevertheless, WCSD had little or no effect on
fibrocyte phenotype in terms of other monocyte/macrophage (CD11b, CD68, CD206)
and fibrosis markers (α-sma, HSP47, Col I) (not shown). The BAL from these mice was
also assessed for fibrocyte accumulation, but no differences were found in the percent
fibrocytes between vehicle and WCSD-treated mice (not shown). However, there was a
39

slight reduction ~(15%) in the total number of cells collected from BAL of WCSDtreated mice compared to the vehicle-treated mice. These data suggest that WCSD is an

Figure 20. Adhesion to Fibronectin of Vav1-EGFP- and Vav1-Cre+;EGFP+
Fibroblasts. (A) Unpassaged fibroblasts from Vav1-Cre;mTmG mice (n=3) were
collected using accutase to preserve cell surface receptors, before being plated in 96-well
plates that were precoated with fibronectin at concentrations of 0, 1, 3, 10, and 30 µg/ml.
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After a 1 hour incubation at 37°C, the cells were fixed and gently washed before being
observed and photographed on a fluorescent microscope. Representative photos at 2.5x
and 10x magnification are shown, (B) with a phase contrast image to demonstrate cell
shape. (C) Quantification of the Percent Area occupied of Vav1-Cre+;EGFP+ (green)
and Vav1-EGFP- (red) cells using ImageJ software. Percent area is shown in terms of the
average ± SD of each of 3 saline and 3 bleomycin samples.
effective inhibitor of the accumulation of fibrocytes in the lung tissue, though there was
no effect of WCSD on the percent of fibrocytes in the BAL except in the reduction of the
total number of BAL cells collected.
In histological studies, lung tissue from vehicle showed very high levels of
collagen deposition and inflammatory cell infiltration, while lung tissue from WCSD
treated mice were close in appearance to saline-treated mice. Skin tissue from
bleomycin/vehicle treated mice showed increased dermal thickening and a near total loss
of fat, while skin tissue from WCSD treated mice showed reduced dermal thickening
compared to vehicle treated mice, as well as preservation of the fat layer. Overall, the
skin from WCSD treated mice had an intermediate phenotype between saline and
bleomycin/vehicle treatments. These data indicate that WCSD is effective at mitigating
the profibrotic effects of bleomycin in multiple tissues in our mouse model.
To examine the effect of WCSD on the production of proteins associated with
fibrosis and with vascular leakage in the lungs of the mice from this experiment, identical
lobes were collected from each mouse, homogenized, and extracts were made for
Western blot analysis (Figure 22). Prior to analysis, samples were normalized using βactin to standardize protein loading. For Col I, bleo+veh treated mice had over a threefold increase in collagen expression compared to saline treated mice, and WCSD
treatment reduced collagen expression by about 50%. Bleo+veh treated mice showed a
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two and half-fold increase in expression of the myofibroblast marker, alpha-smooth
muscle actin (α-sma), compared to samples from saline, and WCSD treatment reduced αsma expression by 50% in the lungs. Next, tenascin, a protein that is highly expressed
during injury and disease was compared between the samples. Bleo+veh saw a six-fold
increase in expression of tenascin compared to saline, and WCSD treatment reduced this
increase by 50%. HSP47 expression was also examined in these samples due to its
importance in collagen production, and as a surrogate marker for myofibroblasts. HSP47

Figure 21. WCSD Inhibits Fibrocyte Accumulation and Fibrosis in the Bleomycin
Mouse. (A) Total lung cells from saline, bleomycin+vehicle, and bleomycin+WCSD
treated mice sacrificed 21 days post pump implantation, and were stained with antibodies
for CD45 and Col I. Scatter plots are presented with Vav1 on the y-axis and Col I on the
x-axis, CD45 was also analyzed replacing Vav1 on the y-axis and similar results were
obtained. (B) Perecent fibrocytes (Vav1+/Col I+) are shown as the average ± SD for each
of the 4 saline, 4 bleomycin+vehicle, and 4 bleoymycin+WCSD sacrificed 21 days post
pump implantation. WCSD significantly inhibited the accumulation of fibrocytes in the
lung of bleomycin-treated mice compared to the mice that received vehicle. (C)
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Representative images from Masson’s sections of the lung and skin from saline,
bleomycin+vehicle, and bleomycin+WCSD mice. Collagen accumulation was inhibited
in the mice that received WCSD compared to the mice that received vehicle in both the
lung and skin. WCSD prevented the complete loss of the fat layer in the skin that was
seen in the vehicle-treated mouse. *p < 0.05
had a seven-fold increase in expression in bleo+veh treated mice compared to saline, and
WCSD treatment reduced HSP47 expression by nearly 90%. Lastly, vascular leakage, a
hallmark of fibrotic diseases, was examined by looking for IgG leakage into the tissue.
The bleo+veh treated lung showed a three-fold increase in the amount of IgG leakage into
the tissue compared to saline, and treatment with WCSD reduced this increase by over
100%. Interestingly, the bleo+WCSD was even lower than saline indicating that WCSD
treatment is an extremely effective way to prevent vascular leakage. Together these data
suggest that WCSD is an effective antifibrotic peptide that both reduces the production of
ECM proteins and myofibroblast markers, as well as preventing the accumulation of
fibrocytes and other inflammatory cells into the tissue possibly by inhibiting vascular
leakage. It is noteworthy that the inhibition by WCSD of fibrocyte accumulation (Figure
21) and the levels of ECM proteins, myofibroblast markers, and vascular leakage were all
>50%.
Human SSc Lung Fibrocytes
To evaluate if CD45+/Col I+ cells could be found in human lung tissue, a lung
tissue sample from a patient diagnosed with SSc was obtained and processed for flow
cytometry by using the methods described above. Briefly, the lung tissue was digested
with collagenase and a single cell suspension was stained with antibodies for CD45, as
well as several other antibodies for monocyte/macrophages and fibrosis. Unstained cells
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and CD45+ only labeled cells were used to establish the gating strategy (Figure 23a). A
cut-off of 1 x 102 marks the maximum value of fluorescence intensity detected for
unstained cells. The addition of CD45 antibody did not change the 1 x 102 cut-off for the
fluorescent channel (AF647) of the monocyte/macrophage and fibrosis markers used in

Figure 22. WCSD Inhibits Fibrosis and Vascular Leakage in the Lung of
Bleomcyin-Treated Mice. (A) Lung tissue from saline, bleomycin+vehicle, and
bleomycin+WCSD mice was collected and proteins were extracted for Western Blotting,
and then stained with antibodies for fibrosis (Col I, α-sma, Tenascin, HSP47) and for
vascular leakage (mouse IgG). Results are shown as a densitometric quantification
(average ± SD) normalized against β-actin. Densitometric quantification was done using
imageJ software. (B) Western blot data is shown for all antibodies used. For comparisons
of saline vs bleo+veh, ^p < 0.05, ^^p < 0.01, ^^^p < 0.001. For comparisons of bleo+veh
vs bleo+WCSD, *p < 0.05, **p < 0.01, ***p < 0.001.
this experiment. As expected CD45+ cells were positive for CD68 and Cd206, while
CD45- cells were negative for these monocyte markers. In strong support of our
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hypothesis that fibrocytes play an important role in fibrotic disease, the levels of Col I, αsma, and HSP47 were at least as high in CD45+ cells as in CD45- cells. The data from
this experiment supports the idea that fibrocytes can be found in the lung tissue of
patients with SSc, that the levels of fibrosis markers are as high or higher in CD45+ cells
than in Cd45- cells, and these human fibrocytes express similar phenotypes to the
fibrocytes detected in the bleomycin-induced fibrosis model for mice.

Figure 23. Human Lung Tissue from SSc Patient Contains Fibrocytes. (A) Total lung
cells from a patient with SSc were left unstained or immunolabeled for CD45 to setup the
gating strategy for further characterization with antibodies labeled with AF647. A cut-off
of 1 x 102 marks the maximum value of fluorescent intensity for CD45 (y-axis) and
AF647 (x-axis). Scatter plots of unstained and CD45 only are shown to validate the
gating strategy. (B) Total lung cells were labeled with antibodies for CD45, for fibrosis
(Col I, α-sma, HSP47), and for additional monocyte/macrophage lineage markers (CD68,
CD206) and plotted for MFI positivity. Plots from unstained cells are shown as blue,
while 1D plots from the referenced antibodies are shown as green for CD45- cells, and
red for CD45+ cells. CD45+ cells from the lung of an SSc patient contained high levels
of expression for Col I, α-sma, HSP47, CD68, and CD206, compared to CD45- cells.
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Single-Cell RNA Sequencing of Primary Adherent Cells from Saline- and
Bleomycin-Treated Lungs
To demonstrate by yet another independent method that cells can co-express
monocyte markers and fibrosis markers, we performed single-cell RNA sequencing.
Unpassaged fibroblast cultures isolated from saline (n=3) and bleomycin-treated (n=3)
Vav1-Cre;mTmG mice were allowed to grow to near confluency before being collected
with accutase and prepared for single-cell sequencing as described in the methods. Using
Partek software, doublets and unlabeled cells were filtered out of the analysis, and the
remaining single cell populations from bleomycin and saline fibroblast cultures were
processed. By applying dimension reduction to the data through the use of principle
component analysis (PCA) and then uniform manifold approximation and projection
(UMAP), the data were segregated into 4 distinct clusters shown in Figure 24. By looking
at the gene expression profiles of the 4 clusters, we were able to further characterize these
clusters and define the groups as: Cluster 1, contained high GFP (monocyte marker)
expression and modest Col I expression; Cluster 2, contained moderately high GFP
(monocyte marker) expression and high Col I expression; Cluster 3 contained modest
GFP (monocyte marker) expression and high Col I; and Cluster 4 contained modest GFP
(monocyte marker) expression, modest Col I expression and high levels of endothelial
markers (Table 1). Interestingly, as summarized in Table 1, almost all genes that are
related to fibroblast activation (vimentin, s1000a4 (FSP1), ACTA2 (α-SMA), Col1a1,
Tagln, Tagln2, and Fn1) were expressed in a high percentage of the cells in all 4 clusters.
Additionally, certain genes characteristic of monocytes/macrophages were found in
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similarly high levels in all 4 clusters, (LGALS3(Mac-3) and LAMP2(Mac-2)). These
observations demonstrate the prevalence of cells that express both fibrosis markers and
monocyte markers in our cultures.
Cluster 4 was of interest because almost all cells in this cluster when derived from
control, saline-treated mice, contained high levels of three endothelial markers (PECAM,
Claudin5, LYVE-1). Interestingly, when derived from bleomycin-treated mice, the
percentage of cells in this cluster increased 3-fold, PECAM continued to be express at
high levels, but the percentage of Cluadin5- and LYVE-1-positive cells decreased
drastically. These observations suggest that endothelial-mesenchymal transformation is
associated with fibrosis and that this transformation involves the loss of certain
endothelial markers. In particular the loss of the tight junction protein claudin5 is likely
to result in the enhanced vascular leakage that we observed in bleomycin-treated mice.
While most genes were expressed at similar levels in cells from saline- and
bleomycin-treated mice, we noted some other interesting counter-examples besides
Claudin5. MMP9 was greatly decreased in expression in cells from bleomycin-treated
mice, raising the possibility that the increased level of collagen in fibrotic disease may
result in part from decreased degradation. Contrary to expectations based on protein
levels, caveolin-1 message is present at increased levels in cells from bleomycin-treated
mice. This may be due to cells trying to compensate for low caveolin-1 protein levels by
expressing increased levels of message. In any case, it remains to be demonstrated
whether this effect occurs in vivo or only in culture.
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Figure 24. UMAP Analysis of Fibroblasts Isolated from Bleomycin and SalineTreated Mice. The UMAP projection of the fibroblasts isolated from both bleomycin
and saline-treated mice is shown. The cells were grouped into 4 clusters using Partek
software to apply dimension reduction to data. The clusters are defined as, Cluster 1
(blue), Cluster 2 (red), Cluster 3 (orange), and Cluster 4 (green).
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Table 1. Summary of Single Cell RNA Sequencing Data. In this table, data are shown
as the percentage of cells positive for fibroblast activation, monocyte, endothelial, and
selected markers of interest gene expression. Genes expressed in ≥26% in all clusters are
highlighted in yellow. - = 0-5%, + = 6-25%, ++ = 26-50%, +++ = 51-100%.
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Discussion
The contribution of CD45+ cells to primary fibroblasts has been controversial
(Kleaveland, Velikoff et al. 2014, Moore-Morris, Guimaraes-Camboa et al. 2014). To
evaluate whether cells from the hematopoietic lineage (CD45+) can contribute to the
population of fibroblasts in fibrosis, we have used multiple complementary systems and
methods to study the levels and phenotypes of CD45+ cells from the fibrotic lung.
Systems used include a bone marrow transplant and transgenic mouse models, as well as
human lung tissue from a patient with scleroderma-associated ILD. Methods used include
flow cytometry and single cell RNA sequencing. All these studies support the concept
that CD45+/Col I+ fibroblasts exist and play a central role in fibrotic lung disease, and
resolve the issues surrounding fibrocytes by using novel methods to confirm their lineage
and contribution to lung fibrosis. We find that:
•

CD45+/Col I+ cells (fibrocytes) increase in number and level of Col during
fibrosis both in the lung tissue and in the BAL

•

The appearance of Col I+ in CD45+ precursors occurs after their recruitment into
the lungs

•

The fibrocytes express higher levels of monocyte/macrophage markers (CD45,
CD16, CD68, CD206) than do CD45+/Col I- cells. They also express high levels
of myofibroblast markers ASMA and HSP47.

50

•

CD45+/Col I+ cells are at first predominant in fibroblast cultures (we define
fibroblasts as cells that bind to tissue-culture plastic, express Col I, and are
spindle-shaped in vitro), but then are lost progressively during passage
o CD45-/Col I+ cells spread more than fibrocytes and thus may crowd them
out despite the fact that fibrocytes can adhere to fibronectin-coated
surfaces at lower fibronectin concentrations
o Fibrocytes do not appear to grow in vitro in the absence of CD45-/Col I+
cells

•

Treatment with a novel, water-soluble version of CSD called WCSD inhibits
fibrocyte accumulation as well as overall Col, Tenascin C, α-sma, and HSP47
levels and vascular leakage. The decreased fibrocyte accumulation may result
both from decreased precursor recruitment due to decreased vascular leakage and
to the decreased differentiation of fibrocytes from CD45+/Col I- precursor
monocytes.

•

WCSD also reverses the pathological effects of systemic bleomycin on the loss of
the transdermal adipose layer.

Identification and Characterization of CD45+ Fibroblasts
To recapitulate the features of ILD seen in patients with SSc or IPF, an animal
model in which bleomycin is delivered systemically via osmotic minipumps (Lee, Reese
et al. 2014) was used to more accurately model the effects of the disease compared to the
more routine model where bleomycin is delivered directly into the lungs. We find that
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there are populations of cells in both control and fibrotic lung tissue that are of
hematopoietic origin, and yet express markers for fibrosis such as, Col I and HSP47, as
wells as expressing other monocyte macrophage markers including CD11b, CD16,
CD68, and CD206. In fibrotic lung tissue, the number of these cells was significantly
increased compared to control lung tissue, and these cells derived from the hematopoietic
lineage in fibrotic tissue also expressed higher levels of collagen.
By looking at the time course for the accumulation of CD45+/Col I+ cells in the
fibrotic lung, we confirmed the association of these cells with the development of
fibrosis. By breaking CD45+/Col I+ cells into two regions, Region I (CD45high/Col I+)
and Region II (CD45+/Col I+), we were able to differentiate between the early
inflammatory response from pump installation, and the later accumulation of these cells
in response to fibrosis. In both saline or bleomycin-treated mice, the number of cells
found in Region I (CD45high/Col I+) remained low 3 days after pump implantation.
After 10 days, the number of cells in Region I (CD45high/Col I+) remained low in the
saline lung, but showed a slight increase in the bleomycin lung. By day 28, the number of
cells in Region I (CD45high/Col I+) had dramatically increased in the bleomycin lung
while remaining unchanged in saline. The results in Region I (CD45+/Col I+) showed an
interesting difference at day 3 compared to what was seen in Region I (CD45high/Col
I+). Both saline and bleomycin lung, had large numbers of CD45+/Col I+ cells in Region
II 3 days after pump implantation, which decreased significantly by day 10. The number
of cells in Region I (CD45+/Col I+) remained relatively unchanged in both saline and
bleomycin lung by day 28, but by this time point the number of cells observed in the
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bleomycin lung was significantly higher than in the saline lung. Our observations support
the idea that CD45+/Col I+ cells (particularly CD45high/Col I+ cells) accumulate in the
lung over time, and that an initial transient increase in the number of CD45+/Col I+ cells
is likely due to the surgery and pump implantation rather than the contents of the pumps.
Because circulating fibrocytes have been reported in both human disease and
various mouse models (Yang, Scott et al. 2002, Galligan and Fish 2012, Russell, Herzog
et al. 2012, Lin, Alrbiaan et al. 2020), we investigated whether we could detect these cells
among circulating PBMCs in the bleomycin pump model. While we did detect an initial
small increase in circulating CD45+/Col I+ cells shortly after pump installation (both
vehicle and bleomycin pumps), this increase did not persist, using antibodies for CD45
and Col I, very low levels of fibrocytes were detected in the blood from both saline and
bleomycin-treated mice. Interestingly, a similar increase in the number of cells in Region
I (CD45+/Col I+) was observed at day 3 for both saline and bleomycin PBMCs, as was
the subsequent decrease. These observations further support the idea that there is an early
inflammatory response to the implantation of the pump that resolves by day 10. These
observations may also suggest that cells of hematopoietic origin may not fully
differentiate into fibroblast-like cells until they reach their target tissue. Despite the fact
that other studies report finding circulating fibrocytes in the PBMCs of mice (Lin,
Alrbiaan et al. 2020), we were unable to detect them even when using several different
antibodies for Col I.
Because Col I is a secreted protein that has been reported to be taken up by cells,
we performed a wide variety of control experiments to rule out the possibility that the
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CD45+/Col I+ cells that we detect picked up Col I from the extracellular matrix in vivo
that had been secreted by CD45-/Col I+ cells. First of all, the antibody that we use to
detect Col I (which we call Pro) was made against the Col Iα1 C-terminal propeptide.
This peptide is cleavage off of Col I prior to its deposition in the extracellular matrix, so
should not recognize Col I derived from the extracellular matrix. Next, one would expect
Col I derived from the extracellular matrix to be bound to the cell surface. However, we
only detected Col I in cells that had been fixed and permeabilized, not in live cells (data
not shown). (Fix-permeabilization was also necessary to detect certain other markers that
we used; namely the macrophage marker CD68 and the myofibroblast markers HSP47
and ASMA). In another approach, we used the Col I chaperone HSP47, which is involved
in the secretion, processing, and stabilization of collagen I (Hagiwara, Iwasaka et al.
2007, Ishida and Nagata 2011) and not present in the extracellular matrix, as a surrogate
marker for collagen production. We found that there are significantly higher levels of
HSP47 in CD45+/Col I+ cells compared to CD45+/Col I- cells. In addition to this
observation, CD45+/Col I+ cells from bleomycin lung contained significantly higher
levels of HSP47 than was found in CD45+/Col I+ cells from saline lung. These data are
consistent with several studies that demonstrate that HSP47 is upregulated in fibrosis
(Kakugawa, Yokota et al. 2013, Lee, Reese et al. 2014, Pleasant-Jenkins, Reese et al.
2017, Miyamura, Sakamoto et al. 2020). Finally, we used transgenic mice that express
EGFP under the control of the Col Iα1 promoter. It is straightforward to detect
endogenous Col I expression in these mice as EGFP, while adsorbed Col I would not be
detected as EGFP. These observations strongly support the idea that BM cells are
recruited into sites of fibrosis and are capable of producing their own collagen and
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contributing to the population of myofibroblasts in the tissue, and is similar to what has
been reported in renal fibrosis (Li, Deane et al. 2007, Jang, Kim et al. 2014, Wang, Meng
et al. 2016).
While most of the experiments used in these studies made use of 10 to 12-week
old C57BL/6 mice to confirm the presence of CD45+/Col I+ cells in the lungs of fibrotic
mice, some of the experiments performed in the study used 24-week old C57BL/6 mice.
These mice had undergone irradiation, and received BM transplants from mice that
express EGFP in all of their cells. This approach allowed us to see if CD45+/Col I+ cells
are in fact BM-derived, and whether the fibrotic response to bleomycin was something
that occurred in both young and old mice. These studies confirmed that all CD45+ cells
from both saline and bleomycin-treated mice were BM derived, and that CD45- cells did
not express EGFP. This study also showed that the strong fibrotic response to bleomycin
was not just limited to young mice, but can also occur in mice that are several months
older. This observation may be useful as many studies make use of relatively young mice
(10 weeks) to study ILD, while most patients that develop ILD are older adults
(Foocharoen, Netwijitpan et al. 2016). Additionally, lung tissue sections taken from the
bleomycin mice not only showed increases in the number of EGFP+ cells, they also
showed that the EGFP+ cells are also positive for Col I. Together these data further
support the idea that during fibrosis, CD45+ cells accumulate in the lung tissue and
express Col I.
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Lineage Tracing of Vav1 Derived Fibrocytes and Fibroblasts
By using Vav1-Cre;mTmG mice, we were able to further assess the contribution
of hematopoietic cells to the population of fibrocytes and fibroblasts, as well as perform
additional experiments to further characterize these cells. Vav1 is expressed early in the
development of hematopoietic cells. In our model these cells are marked by their
expression of EGFP (Georgiades, Ogilvy et al. 2002). These studies allowed for the
monitoring of hematopoietic (Vav1) cells without the use of antibodies, and also for
monitoring of live cultures of Vav1+ cells by fluorescent microscopy. As with our
previous experiments, we detected significant increases in the number of hematopoietic
cells (Vav1-Cre+;EGFP+) that expressed Col I in the lungs of mice that received
bleomycin compared with saline-treated mice. The same result was observed whether we
used Vav1-EGFP or CD45 double labeled with antibodies for Col I; confirming that
Vav1-EGFP expression was a reliable marker for all hematopoietic cells. In addition to
looking at total lung cells, BAL was also isolated from both bleomycin and saline-treated
mice and the same flow cytometric analyses were performed. As with the total lung cells,
there was an increase percentage of Vav1+/Col I+ cells in the BAL from bleomycin lungs
compared to saline. In addition to the increased percentage of Vav1+/Col I+ cells, there
were three times as many total cells in the BAL of bleomycin-treated mice. This
observation is likely due to the increased vascular leakage characteristic of bleomycin
treatment and fibrotic diseases like ILD (Swaney, Chapman et al. 2010, Gendron, Lemay
et al. 2017, Zhao, Tian et al. 2019). These observations on both total lung cells and BAL
cells confirm that Vav1 is a reliable marker for hematopoietic cells that marks the same
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population of cells from our experiments that used CD45 or EGFP+ BM cells to identify
cells of hematopoietic lineage origin.
To further phenotype the Vav1 cells that contribute to fibrosis, a panel of
antibodies for monocyte/macrophage and fibrosis markers was used on cells expressing
Vav1-EGFP from total lung digests and BAL from bleomycin and saline-treated mice. In
the lungs of bleomycin-treated mice, for the monocyte/macrophage markers we found
significant increases in the numbers of cells expressing CD11b, CD16, and CD68
compared to the lungs from saline-treated mice. In cells isolated from the BAL, there
were significant increases in the numbers of cells expressing CD11b and CD16 in the
bleomycin BAL. These data further confirm that there are increased numbers of
monocyte/macrophages in both the lung and BAL of bleomycin treated mice. When the
fibrosis markers were analyzed in Vav1-Cre+;EGFP+ cells from bleomycin and salinetreated mice, we found bleomycin-treated mice exhibited significant increases in the
number of cells expressing Col I, using antibodies against both the collagen Iα1 Cterminal propeptide and the Collagen Iα1 C-terminal telopeptide in cells from both the
lung and BAL of bleomycin. Higher numbers of cells expressing α-SMA and HSP47
were also detected in the bleomycin lung, but the difference was not significant.
However, the level of HSP47 in these cells from bleomycin-treated mice was much
higher than in saline-treated mice. Together these data indicate that fibrosis is
characterized by increased numbers of hematopoietic lineage cells in both the lung and
BAL, and that these cells express high levels of fibrosis markers.
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Since hematopoietic lineage (Vav1-EGP+) cells were shown to express fibrosis
markers, we wanted to determine the contribution these cells would make to fibroblast
cultures prepared under routine conditions. In unpassaged fibroblast cultures, there were
relatively high numbers of Vav1-Cre+;EGFP+ cells observed by fluorescent microscopy
from day 1 (when unbound cells are removed) to confluency for cultures from both
bleomycin- and saline-treated mice. The Vav1-Cre+;EGFP+ cells appeared to be smaller
in size than the Vav1-EGFP- cells and appeared to be less spread than the Vav1-EGFPcells. After the fibroblasts reached confluency, the cells were passaged. We noted a
dramatic decrease in the number of Vav1-Cre+;EGFP+ cells in the fibroblast cultures.
The number of Vav1-Cre+;EGFP+ cells decreased even further after an additional
passaging resulting in cultures with almost no Vav1-Cre+;EGFP+ cells. To confirm the
visual observations, flow cytometry was performed on the fibroblast cultures at the
various passages. Similar high numbers (>75% of total cells) of Vav1-EGP+ or CD45+
cells were observed in unpassaged cells. The decreases in Vav1-Cre+;EGFP+ cells vs
passage detected by flow cytometry totally paralleled the decreases observed by
fluorescent microscopy. These observations indicate that cells of hematopoietic origin are
capable of growing in typical fibroblast cultures, but may ultimately be outcompeted for
space by resident fibroblasts due to the enhanced ability of the resident fibroblasts to
spread. This observation may be why many researchers have overlooked the contribution
of hematopoietic cells to fibroblast populations, as experiments are typically done with
fibroblasts that are at least in passage 3.
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Since it appears that while fibroblasts derived from the BM can grow in fibroblast
cultures, but may be outcompeted for space by resident fibroblasts, experiments were
preformed to examine whether BM derived fibroblasts could grow with reduced
competition for space. Initially, CD45+ cells were isolated from the lung tissue of both
saline and bleomycin-treated mice, but were unable to grow and expand under normal
fibroblast conditions. However, when total lung digests were plated at 50% the routine
seeding density, the Vav1-Cre+;EGFP+ cells were able to grow and expand to the point
that the Vav1-Cre+;EGFP+/Col I+ fibroblasts were >90% of the cells in the culture.
These data further support the idea that cells from the hematopoietic lineage contribute to
the fibroblast population in vivo and in vitro prior to passage.
To further evaluate whether Vav1-Cre+;EGFP+/Col I+ fibroblasts require Vav1EGFP-/Col I+ cells to grow, we used BAL cells (>95% CD45+) as the source of Vav1Cre+;EGFP+/Col I+ fibroblasts. These cells were cultured either using routine fibroblast
growth media, conditioned media from Vav1-EGFP- fibroblast cultures, or in co-culture
with established cultures of Vav1-EGFP- fibroblasts. These experiments revealed that
with no additional stimulation, the CD45+ cells failed to grow and expand in culture; and
that CD45+ cells grown in conditioned media had some growth and expansion, but
ultimately failed to assume a spindle shape and grow to confluency. It was only in coculture that the CD45+ cells were able to grow well and uniformly assume a spindle
shape. These data support the idea that both secreted factors, ECM proteins, and/or cell
contact provided by Vav1-EGFP- fibroblasts may be critical in allowing BM derived
cells to grow and assume the spindle shape characteristic of fibroblasts.
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The ECM protein fibronectin is upregulated in the lung of many different fibrosis
related injuries, and plays a role in the adhesion, activation, and recruitment of fibroblasts
in the lung (Roman, Ritzenthaler et al. 2004, Muñoz-Esquerre, Huertas et al. 2015,
Klecker and Nair 2017, Ghavami, Yeganeh et al. 2018). For these reasons and because
fibronectin is well-known as a protein capable of mediating fibroblast adhesion, we
performed an experiment to compare the ability of Vav1-Cre+;EGFP+ and Vav1-EGFPfibroblasts to adhere to plates coated with fibronectin. Cells harvested from unpassaged
fibroblast cultures containing both Vav1-Cre+;EGFP+ and Vav1-EGFP- cells were plated
in 96-well plates coated with a range of concentration of fibronectin. Interestingly, at the
lowest concentration of fibronectin tested (1 μg/ml in the coating solution), near-maximal
attachment of Vav1-Cre+;EGFP+ cells occurred. In contrast, the adhesion of Vav1EGFP- cells continued to increase up to the highest concentration of fibronectin tested
(30 μg/ml in the coating solution). These data suggest that Vav1-Cre+;EGFP+ cells are
highly responsive to the ECM protein fibronectin and raise the possibility that in fibrotic
diseases the increased concentration of ECM proteins leads to activation of fibroblasts
derived from the hematopoietic lineage.
WCSD Decreases Fibrocyte Levels and Fibrosis in the Bleomycin Lung
Previous data from our lab has shown that PBMCs from patients with SSc-ILD
express lower levels of caveolin-1 than healthy controls, and that the use of a caveolin
surrogate peptide, CSD, is effective at blocking the recruitment of these cells towards
several chemokines in vitro and their expression of Col I (Reese, Dyer et al. 2013, Lee,
Perry et al. 2014, Reese, Perry et al. 2014). In addition, CSD inhibits Col I expression by
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myofibroblasts and mesenchymal stem cells (Tourkina2005, Lee2019). To address the
importance of fibrocytes in lung fibrosis, a novel water-soluble version of CSD (WCSD)
was used to evaluate the effects of the peptide on fibrocyte accumulation and the
progression of fibrosis in bleomycin-treated mice. The mice received bleomycin by
osmotic minipump for 7 days, at which point the mice were given daily I.P. injections of
either WCSD or vehicle until they were sacrificed at day 21. Treatment with WCSD was
effective in reducing the number of CD45+/Col I+ cells in the lungs compared with
vehicle treated mice, even though treatment with WCSD did not begin until after
bleomycin administration had stopped. Our experimental design does not allow us to
determine whether WCSD inhibited the recruitment of fibrocyte precursors into the lungs
or inhibited the differentiation of the precursors into Col I+ fibrocytes; based on previous
studies, however, we expect that WCSD is inhibiting both processes. While WCSD
reduced the number of fibrocytes, it did not significantly alter their phenotype.
Additionally, lung and skin tissue were collected from these mice and Masson’s
trichrome staining was performed. WCSD was effective at inhibiting the amount of
inflammation (cellularity) and collagen deposition in the lungs of the bleomycin-treated
mice, compared to those that only received vehicle. WCSD also prevented the complete
loss of fat in the dermal layer that was seen in mice that only received vehicle treatment.
Lung tissue extracts were also examined by Western blot for their expression of ECM
proteins associated with fibrosis (Col I, Tenascin C), myofibroblast markers (α-sma,
HSP47) (van Amerongen, Bou-Gharios et al. 2008, Hinz, Phan et al. 2012, Cao, Wang et
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al. 2018), and for vascular leakage measured by the amount of IgG in the tissue. WCSD
almost completely inhibited the over-accumulation in the tissue of all of these proteins.
These major beneficial effects of WCSD on fibrosis may result from the direct inhibition
of the expression of Col I, tenascin c, α-sma, and HSP47. They may also result from a
decrease in the recruitment of inflammatory cells as a consequence of the inhibition of
the vascular leakage known to occur in fibrotic lungs (Tang, Zhao et al. 2014, Gendron,
Lemay et al. 2017). It is also possible that inhibiting the expression of certain ECM
proteins contributes to the inhibition of the recruitment of inflammatory cells, given that
fibronectin and tenascin c have been shown to promote recruitment in fibrosis(Roman,
Ritzenthaler et al. 2004, Bhattacharyya, Wang et al. 2016).
In other words, WCSD may be preventing BM derived cells from leaving the
circulation and entering the tissue, as well as inhibiting the release of chemo attractants
into the circulation. Together, these data strongly support the idea that WCSD is effective
at inhibiting the progression of fibrosis by reducing the number of BM derived fibroblasts
in the tissue by blocking their recruitment and activation into myofibroblasts.
CD45+/Col I+ Cells in Human SSc-ILD Lung Tissue
To address whether fibrocytes (CD45+/Col I+ cells) could be found in the lungs
of patients with ILD, lung tissue from a patient with SSc-ILD was analyzed by flow
cytometry. These studies revealed a population of fibrocytes from the SSc-ILD lung that
were CD45+/Col I+, and these fibrocytes also expressed the monocyte/macrophage
markers CD68 and CD206, as well as the myofibroblast markers α-sma and HSP47.
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While several other studies have reported detecting fibrocytes in the circulation and BAL
of patients with ILD (Fujiwara, Kobayashi et al. 2012, Borie, Quesnel et al. 2013, Sun,
Zhu et al. 2016, Wollin, Distler et al. 2019), to the best of our knowledge this is the first
report detecting these cells in lung tissue. The data from this experiment show that as in
our animal model for ILD, CD45+/Col I+ can be detected in human lung samples, where
they appear to be contributing to the population of myofibroblasts.
Single-Cell Sequencing of Fibroblasts from the Saline and Bleomycin Lung
The use of single-cell RNA sequencing (scRNA-seq) has become a powerful tool
in the understanding of cell functions, responses to treatments, and disease progression at
the single-cell level (Gao 2018). To fully characterize and understand the populations of
cells that are contributing to the fibroblast populations, we utilized this technique to study
fibroblasts that were isolated from both saline and bleomycin-treated Vav1-Cre+/mTmG
mice. Total lung cells were first isolated and grown under routine conditions till near
confluency before processing for scRNA-seq. By processing the data and applying
dimension reduction using PCA and UMAP, we recognized 4 clusters of cells that could
be characterized by their gene expression profiles. The cells in Cluster 1 expressed the
highest levels of GFP which marks hematopoietic-lineage derived cells, as well as
expressing modest levels of Col I. Cluster 2 expressed moderately high levels of GFP,
and high levels of Col I. The cells in cluster 3 contained modest levels of GFP and high
levels of Col I. The cells in cluster 4 expressed moderate levels of both GFP and Col I,
but expressed high levels of endothelial markers. Cells from both saline and bleomycin
fell into these clusters, and overall shared fairly similar features.
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To further characterize and compare the clusters, we examined several genes
associated with fibroblast activation and monocyte markers. Interestingly, there were
many genes for fibroblast activation expressed in high levels across all 4 of the clusters.
The intermediate filament protein, vimentin, which plays an important role in the
migration, growth, and proliferation of fibroblasts, and is associated with their response
to injury, was highly expressed in all clusters (Mendez, Restle et al. 2014, Cheng, Shen et
al. 2016). FSP1, a protein that is expressed by fibroblasts in tissue remodeling and has
also been used to identify fibroblasts that have undergone epithelial to mesenchymal
transition (EMT) in different organs, was high in all clusters (Österreicher, PenzÖsterreicher et al. 2011). Other genes (α-sma, Col I, Transgelin [Tagln], Tagln2,
fibronectin 1 [FN1]} associated with fibroblasts as well as their response to injury were
expressed in all four clusters. In summary, all the clusters are composed of cells with a
variety of fibroblastic characteristics.
We further examined the 4 clusters for their expression of various hematopoietic
lineage and monocyte markers. Most important, while clusters 1 and 2 contained high
levels of EGFP, clusters 3 and 4 contained moderate levels of EGFP when derived from
saline-treated mice, but contained much higher levels when derived from bleomycintreated-mice. Certain genes considered to be monocyte markers (Galectin-3 [LGALS3] or
Mac-2) and lysosome-associated membrane protein 2 (LAMP2 or Mac-3) were expressed
by a high percentage of cells in all 4 clusters. Therefore, it is difficult to simply state that
any particular cluster represents fibrocytes and that any particular cluster represents
resident fibroblasts(Dong and Colin Hughes 1997, Chueh, Lin et al. 2015). This difficulty
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may result from the fact that all of these cells have been removed from the in vivo
environment and been cultured on plastic in the presence of 10% serum that may cause a
convergence in the phenotypes of fibroblasts from saline- and bleomycin-treated mice.
Experiments in which cells are analyzed directly after release from tissue may help
overcome this ambiguity. Given these caveats, we believe that the clusters that we have
observed for the most part represent: Cluster 1, Fibrocytes; Cluster 2, Myofibroblasts
derived from fibrocytes; Cluster 3, Resident fibroblasts; Cluster 4, Cells undergoing
endothelial-mesenchymal transformation.
Monocyte markers (e.g., CD68, CD206, GFP, CD45, CD16, Colony Stimulating
Factor 1 Receptor [CSFR1], F4/80, and CD11b) are expressed at high levels in clusters 1
and 2. These genes are expressed at moderate levels in clusters 3 and 4, but among this
group only GFP was expressed in high levels of cluster 3 and 4, and that was only in cells
from the bleomycin-treated mice.
When the 4 clusters were examined for their expression of various endothelial
markers, there were no genes expressed by a high percentage of cells across all 4 clusters.
In fact, clusters 1-3 contained almost no cells expressing endothelial markers. Platelet
endothelial cell adhesion marker (PECAM-1) was the only gene that was expressed in a
high number of cells from both bleomycin and saline-treated mice in cluster 4. Claudin
and lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1) were expressed in
cells from both bleomycin and saline mice, but only saline contained high (≥50%)
numbers of cells expressing these genes. Studies on whether the loss of the tight junction
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protein claudin5 is related to the increase in vascular leakage will be an exciting topic for
future research.
Additionally, we examined the expression of matrix metalloproteinase 9 (MMP-9)
and Caveolin-1 (cav-1), two genes of interest to this study. MMP-9, expressed by a wide
variety of cell types including monocyte/macrophages and fibroblasts, is an interesting
molecule that plays a profibrotic part as well as a role in the resolution of fibrosis. This
dynamic role of MMP-9 is seemingly temporal, where MMP-9 has been shown to
promote a fibrotic response early, while aiding in the resolution of fibrosis at later stages
(Feng, Ding et al. 2018, Wang, Gao et al. 2019, Wang, Liu et al. 2019). When we
examined our clusters for MMP-9 expression, we found that expression was largely
limited to clusters 1 and 2, with little to no expression in clusters 3 and 4. Interestingly,
the number of cells expressing MMP-9 was highest in saline for both clusters 1 and 2.
This increase in MMP-9 expression in saline cells may reflect the fact that these cells
have left an in vivo environment with no fibrotic stimuli, and are now being cultured on
tissue culture plastic potentially initiating a fibrotic response in these cells. Conversely,
an opposite effect was observed when we looked at cav-1 expression in the 4 clusters.
While all clusters had some expression of cav-1, there were only high numbers of cells
expressing cav-1 in clusters 2-4. Interestingly, the percentage of cells expressing cav-1
was higher for cells from bleomycin-treated mouse compared to saline in all clusters.
This is somewhat unexpected, as previous data from our lab showed that both in the
bleomycin animal model and in patients with SSc-ILD, cav-1 expression was decreased
in fibrocytes, monocytes, and other fibrosis related cell types (Lee, Reese et al. 2014,
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Reese, Perry et al. 2014). However, this observation may reflect the fact that now that
these cells are out of the bleomycin/fibrosis environment, they may have increased their
expression of cav-1 to make up for any loss that was occurring due to the fibrotic stimuli.
These data further suggest that by removing these cells from their in vivo environment
and placing them on TC plastic, we are potentially inducing changes to the both the types
of cells and their phenotypes that aren’t truly reflective of the populations of fibroblasts
and fibroblast precursors seen in vivo.
Summary
In summary, the results of these studies strongly suggest that during fibrosis cells
from the hematopoietic lineage that express Col I and other fibrosis markers increase in
number, and that their differentiation into these fibroblast precursors primarily occurs
once they are in the target tissue. Previous studies may have overlooked the contributions
of these cells to the fibroblast populations, since they disappear from in vitro cultures
with passaging and are difficult to detect using IHC. These studies highlight several
potential therapeutic targets (using WCSD or other treatments), including the recruitment
and differentiation of fibrobcytes, as well as receptors that may interact with ECM
proteins like fibronectin to promote adhesion and differentiation of these cells.
Limitations
There are several limitations to the experiments performed in this study for a
variety of different reasons, and which could be addressed in future experiments.
Characterization of the phenotype of hematopoietic derived cells would have benefited
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from a more in-depth analysis using the Col-EGFP mice, rather than just the Vav1Cre/mTmG mice. By using the Col-EGFP mice, we would be able to provide a more
precise characterization of CD45+/Col-EGFP+ cells rather than having to rely on Vav1Cre+;EGFP+ cells for this characterization, or through the use of antibodies for CD45
and Col I. Unfortunately, limited numbers of Col-EGFP mice and equipment failures
prevented these analyses for this study. Another area that could benefit from additional
investigation would be further expanding the growth conditions for isolated CD45+ and
BAL cells in culture. While we identified that hematopoietic cells (Vav1-Cre+;EGFP+)
were highly responsive to the ECM protein, fibronectin, and that fibronectin promoted
their adhesion, there were no experiments performed to see how fibronectin and other
ECM proteins affected the growth of CD45+ or BAL cells isolated from the lung. Further
investigation may elucidate the importance of these molecules, and whether the presence
of resident fibroblasts is required or not. One final limitation for this study appears to be
the use of cultured fibroblasts versus total lung cells in our scRNA-Seq experiments. Our
data suggests that cells contributing to fibroblast populations in vivo change their
phenotypes in response to being cultured on TC plastic. By looking at cells directly
isolated from lung digests, a more accurate gene expression profile can be obtained for
cells from bleomycin and saline-treated mice providing valuable insights into the
mechanisms and processes that are occurring during fibrosis.
Future Directions
As discussed above, to gain a more accurate picture of the gene expression
profiles, future studies could utilize scRNA-Seq to characterize total lung cells isolated
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directly from bleomycin and saline-treated mice. In addition to this change, we will also
use scRNA-Seq to evaluate total lung cells from bleomycin-treated mice that have
received WCSD to understand what gene expression profiles have changed, and what
potential gene pathways may be affected by treatment with WCSD. Future studies may
also look at administering WCSD to bleomycin-treated mice at later time points after
fibrosis has been initiated. Furthermore, two drugs that are FDA approved for the
treatment of ILD, pirfenidone and nintedanib, could be evaluated for their effects on
fibrocytes using similar research strategies, which could provide further insight into the
mechanisms and pathways affected by these treatments thus leading to more targeted and
effective therapies. In fact, one study by (Inomata, Kamio et al. 2014) has shown that
pirfenidone was effective at reducing fibrocyte accumulation in the bleomycin-lung, and
may further benefit from using the Vav1-Cre/mTmG mice to lineage trace the cells, and
scRNA-Seq. Combinations of these therapeutics could also be evaluated in our model to
see if there are any synergistic effects of these therapies.
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